Open AccessA randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum
Author(s) -
Atanu Saha,
Santanu Ghosh,
Chhaya Roy,
Makhan Saha,
Krishnangshu Bhanja Choudhury,
Koushik Chatterjee
Publication year - 2015
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.150341
Subject(s) - medicine , oxaliplatin , capecitabine , fluorouracil , folfox , rectum , neoadjuvant therapy , colorectal cancer , total mesorectal excision , chemotherapy , chemoradiotherapy , surgery , cancer , breast cancer
Established as an adjuvant chemotherapy, CapeOX has recently been shown to have radiosensitizer property in a phase I and II studies, with appreciable downstaging and tolerable toxicities.